Please use this identifier to cite or link to this item:
|Title:||Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice|
PRL-3 monoclonal antibody
PRL-3 mouse/human chimeric antibody
|Source:||Guo, K.,Tang, J.P.,Jie, L.,Al-Aidaroos, A.Q.O.,Hong, C.W.,Tan, C.P.B.,Park, J.E.,Varghese, L.,Feng, Z.,Zhou, J.,Chng, W.J.,Zeng, Q. (2012-02). Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 3 (2) : 158-171. ScholarBank@NUS Repository.|
|Abstract:||Antibodies are considered as 'magic bullets' because of their high specificity. It is believed that antibodies are too large to routinely enter the cytosol, thus antibody therapeutic approach has been limited to extracellular or secreted proteins expressed by cancer cells. However, many oncogenic proteins are localized within the cell. To explore the possibility of antibody therapies against intracellular targets, we generated a chimeric antibody targeting the intracellular PRL-3 oncoprotein to assess its antitumor activities in mice. Remarkably, we observed that the PRL-3 chimeric antibody could efficiently and specifically reduce the formation of PRL-3 expressing metastatic tumors. We further found that natural killer (NK) cells were important in mediating the therapeutic effect, which was only observed in a nude mouse model (T-cell deficient), but not in a Severe Combined Immunodeficiency' (scid) mouse model (B- and T-cell deficient), indicating the anticancer effect also depends on host B-cell activity. Our study involving 377 nude and scid mice suggests that antibodies targeting intracellular proteins can be developed to treat cancer. © Zeng et al.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 9, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.